Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cellectis S.A. ADR (NQ: CLLS ) 1.800 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cellectis S.A. ADR < Previous 1 2 3 4 5 6 7 Next > Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 October 30, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress October 22, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety September 03, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors August 26, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer August 07, 2024 From Cellectis Inc. Via GlobeNewswire CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Cellectis Provides Financial Results for the Second Quarter 2024 August 06, 2024 From Cellectis Inc. Via GlobeNewswire FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment August 01, 2024 From Cellectis Inc. Via GlobeNewswire FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment July 25, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 June 28, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing June 20, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications June 12, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia June 04, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024 May 29, 2024 From Cellectis Inc. Via GlobeNewswire CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024 May 28, 2024 CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Cellectis Reports Financial Results for First Quarter 2024 May 28, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 May 27, 2024 From Cellectis Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 07, 2024 Via Benzinga Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca May 06, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Appoints Arthur Stril as Interim Chief Financial Officer May 02, 2024 From Cellectis Inc. Via GlobeNewswire CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023 April 29, 2024 CLLS stock results show that Cellectis missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. Via InvestorPlace Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 April 29, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs April 22, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs April 10, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting April 08, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) January 16, 2024 From Cellectis Inc. Via GlobeNewswire Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 December 22, 2023 From Cellectis Inc. Via GlobeNewswire Cellectis’ Shareholders Meeting to be Held on December 22, 2023 November 17, 2023 From Cellectis Inc. Via GlobeNewswire Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca November 15, 2023 From Cellectis Inc. Via GlobeNewswire Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023 November 06, 2023 From Cellectis Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
